Resultados de la búsqueda 151-160 of 3705 for charcoal-activated-oral-route
Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...
... oral chemotherapy regimens. Finally, this study will be the first to track ... The purpose of this study is to evaluate whether the administration of ...
Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...
The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as ...
Rochester, Minn. The aim of this study is to study the efficacy and safety of our short and long one-day protocols for TMP-SMX graded administration in ...
... oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) ...
... (Oral Anti-Platelet) agents. In addition to exploring ED treatment patterns and success of both ischemic and bleeding risk stratification prior to definition ...
... activating Protein (NAP) (MV-s-NAP) in Patients ... administration of MV-s-NAP in patients with metastic breast cancer. ... activating Protein (NAP) (MV ...
A "Registry" is a list of basic information about people who have a certain disease or condition in common. These immune deficiency diseases are thought to be ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?